In phase Ia/Ib and randomized phase II clinical trials, tiragolumab (an anti-TIGIT antibody) had a tolerable safety profile with promising efficacy (most notably in patients with non-small-cell lung cancer), and clinical trials designed to assess the safety and efficacy of TIGIT inhibitors in patients with RCC are currently ongoing. This evidence concerns the gene TIGIT and renal cell carcinoma.